ASX Confession Season got into full swing yesterday with Cochlear’s guidance downgrade that saw over $4bn in shareholder value wiped out. It is that time that happens every year – a period that fund managers dread and short sellers quietly anticipate. It has no official name on the ASX calendar, no regulatory trigger, and no fixed start date. It is known in market circles simply as Confession Season. If Cochlear’s (ASX:COH) devastating update yesterday is any guide, the 2026 edition has well and truly begun. And it has only just begun.
What Is ASX Confession Season?
Confession Season is the informal name given to the period (typically running from late April through to mid-May) during which ASX-listed companies release trading updates ahead of their full-year results. For companies whose financial year ends on 30 June, this window falls approximately 10 to 14 weeks before year-end: late enough for management to have a reasonably clear picture of how the year will land, and early enough that the ASX’s continuous disclosure obligations compel them to update the market if that picture has materially changed.
The name is apt. Companies that have been quietly managing expectations downward in analyst briefings, attributing soft quarters to timing or one-offs, and maintaining full-year guidance long past the point of credibility, eventually run out of road. They confess. Usually via an early morning ASX announcement, usually with a cluster of explanatory factors, and usually accompanied by a share price move that suggests the market had been giving them the benefit of the doubt they never deserved.
The asymmetry of these events is notable. When a company upgrades guidance during Confession Season, the share price tends to move modestly — analysts already had a sense of it. When a company downgrades, particularly a premium-rated stock that the market has priced for perfection, the reaction can be ferocious.
Cochlear Is the Case Study
Cochlear delivered precisely this dynamic yesterday. The company was the last you’d expect it to happen to – a globally dominant player in cochlear implants, consistently rated among the highest-quality businesses on the ASX, and historically carried at 40–50x earnings. But this company cut its FY26 underlying net profit guidance from A$435–460m to A$290–330m: a reduction of roughly 30% at the midpoint. Accordingly, the share price fell over 40%.
The five headwinds cited (weaker US referral volumes, Middle East disruption, gross margin deleverage from reduced production, an accelerated restructuring charge, and a sharply stronger Australian dollar) did not each appear overnight.
The AUD had been strengthening since late 2025. Hospital capacity constraints in Italy and Spain had been visible in sector data for months. The softening of US consumer sentiment, which Cochlear explicitly identified as affecting discretionary healthcare decisions, had been a well-documented macro theme since the beginning of calendar 2026.
Yet Cochlear’s guidance had remained intact up until the market release. That is the essence of Confession Season: not that companies are deceiving the market, but that the gap between internal confidence and external disclosure narrows rapidly as year-end approaches, and when it finally closes, it does so all at once.
The Macquarie Conference: Ground Zero for Confessions
The single most concentrated catalyst for Confession Season disclosures is the Macquarie Australia Conference, held annually in Sydney in the first week of May. The conference is the largest gathering of Australian-listed companies and institutional investors on the calendar — over 100 companies, more than 800 institutional investors across three days — and it performs a function that is simultaneously celebratory and ruthlessly exposing.
CEOs and CFOs are required to stand in front of rooms full of sophisticated investors and present their outlook. For companies carrying guidance that internal numbers no longer support, the conference creates a binary choice: front-run the disclosure before the event, or face the prospect of fielding direct questions from investors who have done their own channel checking. Most choose the former. The two weeks surrounding the Macquarie Conference consequently see a disproportionate share of the year’s earnings guidance downgrades. Cochlear has provided the opening act.
Five ASX Stocks That Could Be Next
1. ResMed (ASX:RMD)
ResMed (ASX:RMD) is the most obvious candidate. The sleep apnoea device maker has significant US revenue exposure and, like Cochlear, has been a beneficiary of the premium multiple afforded to dominant medical device businesses. Management has consistently characterised US demand as robust, but the same dynamic Cochlear identified — US consumers deferring or avoiding discretionary health interventions — is directly relevant to CPAP device uptake in the adult segment. FX is also a headwind. RMD has maintained its earnings trajectory through the first three quarters of FY26, but the Q4 finish now looks harder.
2. Domino’s Pizza Enterprises (ASX:DMP)
Dominos (ASX:DMP) has been in strategic transition mode for the better part of two years, closing underperforming stores across Japan and Europe and restructuring its franchisee economics. Management has pointed to green shoots in same-store sales data. However, consumer confidence in Japan and Germany (two of its largest markets) has deteriorated meaningfully in calendar 2026, and the cost base has not yet fully reset. A business still rebuilding credibility with the market after multiple disappointments is precisely the profile that Confession Season tends to claim.
3. Lovisa Holdings (ASX:LOV)
Lovisa operates over 900 fast fashion jewellery stores globally, with the United States its most important growth market. Like Cochlear, the company derives the bulk of its revenue offshore, making the AUD’s rise to 71 US cents a direct earnings headwind. More fundamentally, Lovisa’s US customer is a discretionary spending consumer in the lower-to-middle income bracket — exactly the cohort now registering historic low confidence readings. First-half results were solid, and management retained full-year guidance, but the second half started against a materially tougher US macro backdrop than the first.
4. James Hardie Industries (ASX:JHX)
James Hardie generates the majority of its revenue from the North American residential construction market. The company has already navigated one guidance revision in the current cycle, but management has been deliberate in framing recent softness as temporary, tied to housing starts normalisation rather than structural demand destruction. If the US consumer pullback proves deeper or more durable than anticipated — and tariff uncertainty continues to suppress home renovation activity — the path back to growth that Hardie’s current valuation implies becomes narrower.
5. Webjet (ASX:WEB)
Webjet, as an operator of both B2B travel technology and direct consumer travel booking, is exposed to any contraction in discretionary travel spend. The company has benefited from a sustained post-COVID travel boom that has gradually moderated. International tourism data out of Europe and North America has softened in recent months, and the Middle East disruption that cost Cochlear up to A$10m in provisions will have flow-on effects for travel routing and demand in affected corridors.
The Common Thread
None of these companies are structurally broken. Several are among the highest-quality businesses on the ASX. That is precisely what makes Confession Season dangerous for investors who conflate quality with immunity from earnings risk. Cochlear is the highest-quality cochlear implant business in the world. It still fell 40% today.
The pattern now is familiar: global macro deterioration, an Australian dollar that punishes offshore earners, and US consumer sentiment at historic lows producing unexpected softness in categories that seemed defensible. Any company carrying full-year guidance set against different assumptions, with concentrated offshore revenue, and a premium rating that leaves no margin for error, is carrying Confession Season risk. The Macquarie Conference starts in less than two weeks. Watch carefully.
